Discuss This Disease

4 free views remaining today

autosomal dominant adult-onset proximal spinal muscular atrophy

Description

**Autosomal Dominant Adult-Onset Proximal

Additional Characteristics

  • autosomal
  • dominant
  • adult-onset
  • proximal

Signs and Symptoms

Symptoms of Autosomal Dominant Adult-Onset Proximal Spinal Muscular Atrophy

Autosomal dominant adult-onset proximal spinal muscular atrophy (SMA) is a rare genetic disorder characterized by progressive muscle weakness and wasting. The symptoms of this condition can vary from person to person, but here are some common signs and symptoms:

  • Muscle Weakness: Muscle weakness is the most common symptom of autosomal dominant adult-onset proximal SMA. It typically starts in adulthood and progresses slowly over time.
  • Fasciculations: Fasciculations, or muscle twitches, can also be a symptom of this condition.
  • Amyotrophy: Amyotrophy, which refers to wasting away of muscles, is another common symptom of autosomal dominant adult-onset proximal SMA.
  • Cramps: Muscle cramps are also a possible symptom of this condition.
  • Tremors: Tremors can occur in some individuals with autosomal dominant adult-onset proximal SMA.

Clinical Features

According to clinical resources, the clinical features of autosomal dominant adult-onset proximal SMA include:

  • VAPB mutations: Mutations in the VAPB gene are associated with this condition.
  • Adult-onset: The symptoms typically start in adulthood, as opposed to childhood or infancy.

References

  • [6] Clinical resource with information about Adult-onset proximal spinal muscular atrophy autosomal dominant and its clinical features, VAPB, available genetic testing options.
  • [10] Proximal SMA is characterized by symmetrical muscle weakness, more pronounced for proximal than distal limb muscles, and generally affecting the legs.

Additional Symptoms

Diagnostic Tests

Diagnostic Tests for Autosomal Dominant Adult-Onset Proximal Spinal Muscular Atrophy

Autosomal dominant adult-onset proximal spinal muscular atrophy (SMA) is a rare genetic disorder that affects the muscles. The diagnostic tests for this condition are crucial in confirming the diagnosis and ruling out other conditions.

Key Diagnostic Tests:

  • Genetic Testing: This is the primary test used to diagnose autosomal dominant adult-onset proximal SMA. Genetic testing can confirm 95% of cases by identifying problems with the SMN1 gene [4][6]. A blood sample is taken, and the genetic material is analyzed for mutations in the SMN1 gene.
  • Muscle Biopsy: Occasionally, a muscle biopsy may be performed to exclude other conditions that may cause similar symptoms. However, this test is not typically used as a primary diagnostic tool for autosomal dominant adult-onset proximal SMA [6].

Other Relevant Tests:

  • Clinical tests (30 available): These tests are designed to help diagnose various conditions, including Charcot-Marie-Tooth disease axonal type 2N and adult-onset proximal spinal muscular atrophy [3].
  • Patient-Centered Outcome Measures (PCOMs): This test is used to assess the patient's quality of life and functional status [2][5].

Importance of Genetic Testing

Genetic testing is essential in diagnosing autosomal dominant adult-onset proximal SMA. It can confirm the diagnosis with a high degree of accuracy, allowing for early intervention and management of the condition.

References:

[1] Context result 6 [2] Context result 5 [3] Context result 3 [4] Context result 4 [5] Context result 5 [6] Context result 6

Treatment

Current Drug Treatments for Autosomal Dominant Adult-Onset Proximal Spinal Muscular Atrophy

While there is no specific information available on the context provided about drug treatments for autosomal dominant adult-onset proximal spinal muscular atrophy, we can infer some general information from the search results.

  • Nusinersen: Although not specifically mentioned in the context as a treatment for autosomal dominant adult-onset proximal spinal muscular atrophy, nusinersen is an antisense oligonucleotide that has been approved for the treatment of spinal muscular atrophy (SMA) in general. It works by increasing the production of the survival motor neuron protein (SMN), which is essential for muscle function [4][6].
  • Risdiplam: Another drug, risdiplam, has also been approved for the treatment of SMA. However, its effectiveness specifically for autosomal dominant adult-onset proximal spinal muscular atrophy is not mentioned in the context.
  • Onasemnogene abeparvovec: This gene therapy has been approved for the treatment of SMA and works by providing a functional copy of the SMN1 gene to cells. However, its effectiveness specifically for autosomal dominant adult-onset proximal spinal muscular atrophy is not mentioned in the context.

Current Treatment Strategies

While specific drug treatments may not be available for autosomal dominant adult-onset proximal spinal muscular atrophy, treatment strategies for SMA in general include:

  • Nutritional supplementation
  • Modifying food consistency
  • Optimizing oral intake
  • Positioning and seating alterations [9]

It is essential to consult a qualified specialist or a medical professional for personalized advice on the management of autosomal dominant adult-onset proximal spinal muscular atrophy.

References: [4] - Nusinersen was approved by the FDA in December 2016. [6] - Nusinersen works by increasing the production of SMN protein. [9] - Treatment strategies for SMA include nutritional supplementation, modifying food consistency, and optimizing oral intake.

Differential Diagnosis

Autosomal dominant adult-onset proximal spinal muscular atrophy (SMA) is a rare condition characterized by progressive muscle weakness and wasting in the proximal muscles, typically affecting individuals in adulthood. When considering the differential diagnosis for this condition, several other conditions should be taken into account.

  • Amyotrophic Lateral Sclerosis (ALS): ALS is a neurodegenerative disorder that affects both upper and lower motor neurons, leading to progressive muscle weakness and wasting. While ALS can present with proximal muscle weakness, it typically involves a more widespread distribution of symptoms and a faster disease progression rate compared to autosomal dominant adult-onset proximal SMA.
  • Limb-Girdle Muscular Dystrophy (LGMD): LGMD is a group of genetic disorders that affect the muscles around the shoulders and hips. Some forms of LGMD can present with proximal muscle weakness, but they typically involve additional symptoms such as muscle cramps, cataracts, or cardiac abnormalities.
  • Becker Dystrophinopathy: This is a rare form of muscular dystrophy caused by mutations in the dystrophin gene. It can present with progressive muscle weakness and wasting, particularly affecting the proximal muscles.
  • Spinal and Bulbar Muscular Atrophy (SBMA): Also known as Kennedy disease, SBMA is a rare genetic disorder that affects the spinal cord and brain stem, leading to progressive muscle weakness and atrophy. While it primarily affects the lower motor neurons, some cases can present with proximal muscle weakness.
  • Mutations of the LMNA gene: Mutations in the LMNA gene have been associated with various neuromuscular disorders, including forms of muscular dystrophy that can mimic autosomal dominant proximal spinal muscular atrophy.

It's essential to note that the differential diagnosis for autosomal dominant adult-onset proximal SMA may also involve other conditions not listed here. A comprehensive diagnostic evaluation, including genetic testing and electromyography (EMG), is necessary to accurately diagnose this condition.

References:

  • [4] - This search result mentions that the diagnosis of SMA is established in a proband with a history of motor difficulties or regression, proximal muscle weakness, reduced/absent reflexes, and other characteristic features.
  • [5] - This study highlights the importance of considering adult-onset cases of SMA type 4, which can present with proximal muscle weakness and atrophy.
  • [14] - This reference emphasizes the genetic heterogeneity of proximal SMA beyond infancy, including autosomal dominant forms that can mimic adult-onset proximal SMA.
  • [15] - This search result provides a comprehensive overview of spinal muscular atrophy, including its clinical presentation and diagnostic features.

Additional Differential Diagnoses

Additional Information

rdf-schema#domain
https://w3id.org/def/predibionto#has_symptom_5517
owl#annotatedSource
t375342
oboInOwl#hasOBONamespace
disease_ontology
oboInOwl#id
DOID:0111194
core#notation
DOID:0111194
oboInOwl#hasDbXref
ORDO:209335
oboInOwl#hasExactSynonym
SMAFK
rdf-schema#label
autosomal dominant adult-onset proximal spinal muscular atrophy
IAO_0000115
A spinal muscular atrophy characterized by adult-onset of slowly progressive, proximal muscular weakness with fasciculations and absent/hypoactive deep tendon reflexes, without bulbar or pyramidal involvement that has_material_basis_in heterozygous mutation in VAPB on 20q13.
oboInOwl#inSubset
http://purl.obolibrary.org/obo/doid#DO_rare_slim
rdf-schema#subClassOf
t375175
RO_0002452
http://purl.obolibrary.org/obo/SYMP_0000094
RO_0002488
http://purl.obolibrary.org/obo/HP_0003581
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.